MAPK3, mitogen-activated protein kinase 3, 5595

N. diseases: 647; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.060 Biomarker disease BEFREE The protein levels of the components of the mitogen-activated protein kinase (MAPK) pathway, including the c-Jun N-terminal kinase (JNK) and the extracellular-signal-regulated kinase-1 (ERK1), in cell lines of cervical cancer were detected by Western blot. 31081078 2019
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.060 Biomarker disease BEFREE Tca83 exhibited an E7 to E6 transcript ratio comparable to HeLa (cervix), targeted the ERK1/2 and MMP2 pathways, and was dependent on E6 and E7 to survive and proliferate. 31830929 2019
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.060 Biomarker disease BEFREE We also found that the ERK1/2 signaling pathway is involved in the inhibitory effect of Rap2B knockdown on cervical cancer development. 28390112 2018
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.060 Biomarker disease BEFREE Taken together, these results demonstrate that CK17 induced by the TGF-β1-ERK1/2-MZF1 signaling pathway facilitates metastasis by promoting the acquisition of CSC properties rather than by inducing the EMT process in CC, suggesting that this CK17-related signaling pathway might be a suitable target for the development of therapy for CC metastasis. 28703907 2017
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.060 AlteredExpression disease BEFREE Our results suggest that PPARγ agonists are capable of inducing apoptotic cell death in HeLa cells independently of PPARγ and that inhibition of ERK1/2 activity offers a strategy to enhance the cytotoxicity of PPARγ agonists in the treatment of cervical cancer. 27888104 2017
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.060 Biomarker disease BEFREE These results suggest that expression levels of SKP2, p27 and phospho-MAPK/ERK1/2 may serve as markers for progression in human cervical carcinoma and may also play roles in cervical carcinoma progression and cervical carcinogenesis. 17079005 2007